OSE Immunotherapeutics Announces First Peer-Reviewed Publication in Science Advances on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
OSE and MAbSilico joined their efforts to demonstrate the power of a fully computational
in silico Antibody Discovery and Design platform. The expanded collaboration agreement will now be applied to 10 antibody programs.
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005756/en/
OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) today announced a new collaboration agreement with MAbSilico, a deep technology innovative TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development.
Soupateria able to reopen with new installation of safety shields - Penticton News castanet.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from castanet.net Daily Mail and Mail on Sunday newspapers.